Published in Oncogene on July 08, 2004
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res (2009) 2.36
Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J (2010) 2.33
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol (2012) 2.25
ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J (2007) 1.90
Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol (2009) 1.56
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56
Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol Cell Biol (2010) 1.54
Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem (2012) 1.53
Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest (2016) 1.47
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood (2009) 1.37
Constitutive ERK MAPK activity regulates macrophage ATP production and mitochondrial integrity. J Immunol (2008) 1.30
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia (2011) 1.30
Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxid Redox Signal (2012) 1.27
Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res (2012) 1.25
The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer (2012) 1.12
The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem (2013) 1.11
HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. PLoS Pathog (2014) 1.10
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer (2012) 1.09
Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells (2014) 1.09
Programming cancer cells for high expression levels of Mcl1. EMBO Rep (2013) 1.06
The protein kinase C delta catalytic fragment targets Mcl-1 for degradation to trigger apoptosis. J Biol Chem (2006) 1.04
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med (2012) 1.04
Endoplasmic reticulum stress-induced cell death mediated by the proteasome. Cell Death Differ (2007) 1.03
Concise review: Leukemia stem cells in personalized medicine. Stem Cells (2014) 1.02
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul (2007) 1.01
Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia (2012) 1.00
Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochem Pharmacol (2011) 1.00
Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis (2013) 0.99
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J (2013) 0.99
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene (2015) 0.98
HIV/SIV infection primes monocytes and dendritic cells for apoptosis. PLoS Pathog (2011) 0.98
Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab (2014) 0.97
Opposite regulation of oligodendrocyte apoptosis by JNK3 and Pin1 after spinal cord injury. J Neurosci (2007) 0.97
Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. Mol Cancer Ther (2010) 0.96
TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ (2010) 0.94
Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol (2012) 0.93
The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer (2014) 0.93
Nicotine enhances the antiapoptotic function of Mcl-1 through phosphorylation. Mol Cancer Res (2009) 0.93
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92
Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. Mol Cancer (2011) 0.92
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle (2008) 0.91
Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS One (2012) 0.91
RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther (2009) 0.91
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia (2012) 0.91
Expression and function of bcl-2 proteins in melanoma. Curr Genomics (2008) 0.90
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget (2015) 0.90
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol (2010) 0.90
Beneficial dysregulation of the time course of inflammatory mediators in lipopolysaccharide-induced tumor necrosis factor alpha factor-deficient mice. Clin Vaccine Immunol (2010) 0.89
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther (2009) 0.89
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Adv Enzyme Regul (2008) 0.89
Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer (2011) 0.88
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem (2009) 0.88
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
Anticancer therapy: boosting the bang of Bim. J Clin Invest (2008) 0.87
Dusp5 negatively regulates IL-33-mediated eosinophil survival and function. EMBO J (2014) 0.87
Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer (2011) 0.87
SP-1 regulation of MMP-9 expression requires Ser586 in the PEST domain. Biochem J (2012) 0.86
Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One (2014) 0.85
Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell Death Differ (2014) 0.85
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin. Mol Cancer (2014) 0.84
MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. Sci Rep (2016) 0.84
Transcriptomic profiles of aging in purified human immune cells. BMC Genomics (2015) 0.83
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol (2013) 0.83
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. J Cancer Res Clin Oncol (2013) 0.83
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther (2014) 0.83
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal (2012) 0.83
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget (2015) 0.83
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia (2014) 0.82
Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of Mcl-1. PLoS One (2012) 0.82
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget (2015) 0.81
RAF and antioxidants prevent cell death induction after growth factor abrogation through regulation of Bcl-2 proteins. Exp Cell Res (2013) 0.80
Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. Mol Cancer Ther (2013) 0.80
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs (2009) 0.80
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. World J Surg Oncol (2012) 0.79
Bcl2 Family Functions as Signaling Target in Nicotine-/NNK-Induced Survival of Human Lung Cancer Cells. Scientifica (Cairo) (2014) 0.79
Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer risk. PLoS One (2013) 0.79
A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration. Oncotarget (2013) 0.79
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics (2014) 0.79
MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment. PLoS One (2015) 0.79
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Cancer Res (2016) 0.78
Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem (2014) 0.78
Fucoidan induces caspase-dependent apoptosis in MC3 human mucoepidermoid carcinoma cells. Exp Ther Med (2013) 0.78
Uptake, p53 pathway activation, and cytotoxic responses for Co(II) and Ni(II) in human lung cells: implications for carcinogenicity. Toxicol Sci (2013) 0.77
Hyperbaric Oxygen Reduces Production of Reactive Oxygen Species in Neutrophils from Polytraumatized Patients Yielding in the Inhibition of p38 MAP Kinase and Downstream Pathways. PLoS One (2016) 0.76
Staurosporine resistance in inflammatory neutrophils is associated with the inhibition of caspase- and proteasome-mediated Mcl-1 degradation. J Leukoc Biol (2015) 0.76
Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS One (2012) 0.76
Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells. J Biol Chem (2014) 0.76
Mitotic Stress Is an Integral Part of the Oncogene-Induced Senescence Program that Promotes Multinucleation and Cell Cycle Arrest. Cell Rep (2015) 0.76
Protection from interferon-β-induced neuronal apoptosis through stimulation of muscarinic acetylcholine receptors coupled to ERK1/2 activation. Br J Pharmacol (2016) 0.75
Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain. J Biol Chem (2015) 0.75
Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress. Leuk Res (2015) 0.75
Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified. Oncotarget (2016) 0.75
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med (2011) 0.75
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem (2003) 2.66
p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature (2004) 2.26
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63
Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int (2011) 1.56
Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid (2011) 1.55
Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene (2004) 1.53
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood (2014) 1.50
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci U S A (2008) 1.44
Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest (2005) 1.42
The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle (2005) 1.39
Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci U S A (2010) 1.34
TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol (2009) 1.30
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol (2013) 1.19
N-terminal truncation of antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells. J Biol Chem (2007) 1.17
The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle (2009) 1.10
Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol (2010) 1.10
Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology (2006) 1.06
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04
BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol (2014) 1.02
c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J Cell Biochem (2008) 1.01
Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol (2010) 1.01
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res (2013) 1.01
Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res (2009) 0.99
Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens (2013) 0.93
Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors and Stroma. Aging Dis (2012) 0.93
Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol (2013) 0.93
Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. Mod Pathol (2012) 0.92
Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. J Mass Spectrom (2013) 0.91
Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS One (2012) 0.91
AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant (2011) 0.89
Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. Proc Natl Acad Sci U S A (2012) 0.87
Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant (2012) 0.86
Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. Am J Surg Pathol (2009) 0.86
Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol (2013) 0.85
Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol (2012) 0.85
Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder. J Peripher Nerv Syst (2012) 0.85
Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid (2014) 0.85
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun (2013) 0.84
Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res (2014) 0.83
Matching maternal isodisomy in mucinous carcinomas and associated ovarian teratomas provides evidence of germ cell derivation for some mucinous ovarian tumors. Am J Surg Pathol (2013) 0.82
In vitro approach to predict post-translational phosphorylation response to mixtures. Toxicology (2012) 0.82
The alpha1 subunit of GABAA receptor is repressed by c-myc and is pro-apoptotic. J Cell Biochem (2006) 0.81
The Myc-ARF-Egr1 pathway: unleashing the apoptotic power of c-Myc. Cell Cycle (2011) 0.80
MCL1 increases primitive thymocyte viability in female mice and promotes thymic expansion into adulthood. Int Immunol (2011) 0.80
An approach to investigate intracellular protein network responses. Chem Res Toxicol (2014) 0.80
Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis (2006) 0.80
Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol (2012) 0.80
Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse. Dig Dis Sci (2008) 0.78
Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunol Res (2013) 0.78
Recapitulation of germ cell- and pituitary-specific expression with 1.6 kb of the cystatin-related epididymal spermatogenic (Cres) gene promoter in transgenic mice. J Androl (2005) 0.77
Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens. Diagn Cytopathol (2010) 0.76
Small-molecule high-throughput screening utilizing Xenopus egg extract. Methods Mol Biol (2015) 0.76
AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis (2013) 0.75
Apolipoprotein A-IV-Associated Cardiac Amyloidosis. J Am Coll Cardiol (2017) 0.75